IMPORTANCE Development of transient palmoplantar keratoderma (PPK) with bullous pemphigoid (BP) has only been described in 2 isolated case reports. The clinical significance and the pathophysiologic mechanisms of this association are unknown. 
C auses of acquired palmoplantar keratoderma (PPK) are multiple, including psoriasis, eczema, lichen, and cancer. The occurrence of PPK during bullous pemphigoid (BP) has been exceptionally described. 1, 2 We report herein the clinical course and the immunological profile of 6 patients who presented with transient PPK during the course of BP.
Methods
In our tertiary reference center for autoimmune bullous diseases, 6 patients who developed PPK during the course of BP between January 1, 2015, and December 31, 2017, were identified. Clinical data (including treatment) and serum anti-BP180 and anti-BP230 antibodies were recorded both at baseline and during the course of the disease. The ethics committee, University of Reims Champagne-Ardenne (CPP Est-3 No. 2015-A01342-47), approved the study. After written informed consent was obtained, cytokines concentrations were measured by LEGENDplex technique. Keratinocyte (Cellntec, HPEKas) proliferation was investigated by use of WST-1 (Sigma-Aldrich). Cytokine mRNA expression was determined by RT 2 -qPCR, as previously described.
3,4

Results
Baseline clinical and immunological characteristics of patients with BP are summarized in The PPK appeared on average 6.2 months after BP diagnosis, during a prolonged period of clinical BP activity punctuated with recurrent flares despite treatments ( Figure 1 ) ( Table 2) . In all cases, clinical investigations (including computed tomographic scans) eliminated any association with solid cancer and blood malignant disease. When PPK occurred, BP was uncontrolled, 9 multibullous, with a mean total BPDAI score of 57. High titers of anti-BP180 antibodies were still evidenced in all cases (mean, 122 U/mL [81-150]). The PPK disappeared on average in 4.3 months following additional treatments, including methotrexate, rituximab, prednisone, omalizumab, mycophenolate mofetil, azathioprine, and dapsone. When PPK disappeared, BP remained uncontrolled in 2 patients, whereas 4 patients were in complete remission (CR) receiving therapy.
At last follow-up (mean, 17.2 months), 2 patients were in CR off therapy, 1 in CR receiving dapsone (50 mg/d), and 2 still had an active BP despite being treated with doxycycline and clobetasol (20 g 3 times per week) (case 5), or with methotrexate (15 mg per week) and omalizumab (600 mg every 2 weeks) (case 6). The last patient (case 3) died of a pulmonary infection in CR while receiving therapy 5 months after the regression of the PPK. Besides, serum anti-BP180 antibodies remained elevated for 1 patient or were just over the positive limit for 2 other patients ( Table 2 ). In contrast, the PPK disappeared in all cases.
Preliminary biological investigations using the blister fluids from 2 patients with BP who had active PPK showed that they enhanced keratinocyte proliferation compared with samples from the same patients collected at time of BP relapse 
Key Points
Question What are the clinical and immunologic characteristics of bullous pemphigoid associated with transient palmoplantar keratoderma, an association that has been described very rarely?
Findings In this case series of 6 patients, a transient palmoplantar keratoderma appeared in a severe subtype of bullous pemphigoid with a generalized, multibullous disease associated with high anti-BP180 serum titer and recurrent relapses resistant to superpotent topical corticosteroid therapy. Palmoplantar keratoderma was transient and healed in all cases following bullous pemphigoid control with additional immunosuppressive therapy.
Meaning Palmoplantar keratoderma appeared in patients with an initial severe disease and after a prolonged period of clinical activity punctuated with recurrent relapses; this transient palmoplantar keratoderma could represent a clinical maker of severe, treatmentresistant bullous pemphigoid and may potentially be associated with peculiar pathophysiological mechanisms.
without any PPK ( Figure 2) . Also, when collected at time of PPK, the blister fluids contained a higher level of cytokines such as TNFα (16 vs 3 pg/mL; mean values), IL-17A (106 vs 13 pg/mL), IL-17F (83 vs 2 pg/mL) and IL-22 (118 vs 12 pg/mL), and especially IL-1β (>23 000 pg/mL vs 52 pg/mL) than the autologous samples collected before PPK occurrence.
In contrast, CXCL10 concentration tended to decrease (608 vs 364 pg/mL). Finally, in vitro analysis using a keratinocyte cell line revealed that such increase in cytokine concentration within the blister fluids collected at time of PPK did not affect the expression of IL-1β, TNFα, and CXCL10 mRNA expressions. 
Discussion
To our knowledge, no series of patients with a severe and treatment-resistant BP, a secondary occurrence of PPK, along with a very important and isolated anti-BP180-NC16A autoantibody response (without anti-BP230 antibodies) had been reported. Only 2 isolated observations of BP-associated PPK were previously reported, whereas no data on clinical or long-term immunological evolution profile were available. 1, 2 We found that PPK regressed in all patients after BP therapeutic intensification requiring the use of immunosuppressive treatments, which also allowed BP CR in 4 of 6 cases. In this case series, PPK could not be explained by any specific dermatosis apart from BP. Although acquired PPK and BP resistance to treatment could also have been related to neoplasia, 10 such a hypothesis was excluded in all of these cases. Clinically, PPK did not present with any peculiar characteristic, showing a diffuse, homogeneous, progressive, delimited and yellowish hyperkeratosis without nail involvement. Thus, no further histopathologic analysis was carried out. The PPK appeared to be an original, local and transient complication of severe BP, initially diagnosed with severe acral blisters, which was confirmed by anamnesis in 5 of 6 cases (missing data in case 3).
At the time of PPK, BP was generally resistant to CS therapy, multibullous, and severe as illustrated by BPDAI. 11 The multibullous characteristic could not be recorded at baseline because the initial patient treatment was not performed in our tertiary referral center. The BP severity and extent explained the presence of oral mucosal involvement in 5 of 6 cases, as we have recently shown. 12 The severity of the BP was also evidenced by the need to resort to immunosuppressive therapy following the failure of superpotent topical or oral CS therapy, doxycycline, dapsone, and methotrexate. 5, 6, 9 Alongside clinical severity, BP was immunologically very active with a high serum anti-BP180 antibodies level in all patients, usually without anti-BP230 antibodies at the time of BP diagnosis. When PPK occurred, anti-BP180 antibodies remained elevated. Subsequently, when PPK disappeared, along with CR of BP, anti-BP180 antibodies decreased, except for in 1 patient for whom BP remained active. 7, 8 However, no clear relationship could be evidenced between PPK and the anti-BP180 autoantibodies profiles because anti-BP180 antibodies were still detected in 3 patients after PPK healing. Importantly, most of them had either no or low concentrations of anti-BP230 autoantibodies. Absence of anti-BP230 antibodies was recently shown to be associated with oral involvement, 12 as observed in 5 of these 6 patients.
Conclusions
Herein, we showed an increased concentration of IL-1β, IL-17A, IL-17F, IL-22, and TNFα in the blister fluid of patients when the PPK was present. Those cytokines could act synergistically to produce a feed forward inflammatory response in keratinocytes as previously shown in prepsoriatic skin. [13] [14] [15] Indeed, blister fluid collected at time of PPK increased keratinocyte proliferation. Thus, we hypothesize that such original profile of cytokine expression may favor the development of BP unusual clinical features, such as PPK.
Our results suggest a role of infiltrating cells rather than keratinocytes in the production of IL1β/TNFα/IL-17A/IL-17F/ IL-22 panel. However, keratinocyte proliferation could in turn reduce BP180 surface expression, therefore limiting the autoantibody binding process on which blisters originate, and instead favor PPK formation.
We describe a very unusual occurrence of acquired, but transient PPK in patients with a severe, difficult-to-treat BP with a particular immunologic profile. However, further investigations are required to unravel the pathophysiologic mechanisms leading to PPK formation following blisters in BP, which represents a transient, clinical epiphenomenon associated with treatment-resistant BP disease. 
